Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with breast cancer through a tissue biopsy, with test results showing the cancer's hormone receptor (ER/PR) and HER2 status documented.
- People whose breast cancer falls into one of these categories: hormone receptor-positive (HR+), HER2-positive, or triple-negative breast cancer, as defined by standard testing guidelines.
- People with HER2-positive or triple-negative breast cancer who still have cancer in their lymph nodes after completing chemotherapy before surgery; or people with HR-positive/HER2-negative breast cancer who still have cancer in multiple lymph nodes (a larger number) after chemotherapy and surgery.
- People who have completed at least 8 weeks of standard chemotherapy before surgery, using an anthracycline and/or taxane-based treatment — and, for HER2-positive breast cancer, also including HER2-targeted therapy.
- People aged 18 or older.
- People with a life expectancy of at least 6 months.
- People who are reasonably active and able to carry out daily activities, as measured by a standard health scale (confirm with trial site for exact rating).
- People who are able to understand and are willing to sign a consent form for the study procedures.
- People who are willing and able to follow all study procedures and remain available for the full duration of the study.
Who may not be able to join:
- People who have previously been diagnosed with breast cancer that has spread to other parts of the body (metastatic disease).
- People who have had a different type of cancer in the past, unless there has been no evidence of that cancer for at least 2 years — with exceptions for certain treated skin cancers or early-stage cervical or bladder cancers (confirm with trial site).
- People who are unable to receive CT scan contrast dye for any medical reason.
- People with severe or end-stage kidney disease, where the kidneys are functioning at a very low level (confirm with trial site for exact kidney function thresholds).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kamran Ahmed, Moffitt Cancer Center
Phone: 813-745-1807
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Systemic Metastasis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.